UK markets closed

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3850-0.0175 (-4.35%)
At close: 03:56PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 473.44k
Enterprise value 7.87M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)11.55
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.28

Trading information

Stock price history

Beta (5Y monthly) 0.20
52-week change 3-96.05%
S&P500 52-week change 318.47%
52-week high 315.3000
52-week low 30.3300
50-day moving average 32.0696
200-day moving average 34.0211

Share statistics

Avg vol (3-month) 364.62k
Avg vol (10-day) 328.3k
Shares outstanding 51.18M
Implied shares outstanding 61.18M
Float 8489.35k
% held by insiders 13.91%
% held by institutions 168.50%
Shares short (30 Aug 2023) 445.74k
Short ratio (30 Aug 2023) 41.45
Short % of float (30 Aug 2023) 46.82%
Short % of shares outstanding (30 Aug 2023) 43.89%
Shares short (prior month 30 Jul 2023) 462.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 312 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-91.94%
Return on equity (ttm)-1,129.81%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -22.19M
Net income avi to common (ttm)-31.85M
Diluted EPS (ttm)-43.4600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.7M
Total cash per share (mrq)2.3
Total debt (mrq)10.1M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.25
Book value per share (mrq)-5.35

Cash flow statement

Operating cash flow (ttm)-20.79M
Levered free cash flow (ttm)-8.33M